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Abstract
O-linked glycans of secreted and membrane bound proteins play an important role in the 
pathogenesis of pancreatic cancer by modulating immune responses, inflammation, and 
tumorigenesis. A critical aspect of O-glycosylation, the position at which proteins are glycosylated 
with N-acetyl-galactosamine on serine and threonine residues, is regulated by the substrate 
specificity of UDP-GalNAc: polypeptide N-acetylgalactosaminyl-transferases (GalNAc-Ts). Thus, 
GalNAc-Ts regulate the first committed step in O-glycosylated protein biosynthesis, determine 
sites of O-glycosylation on proteins, and are important for understanding normal and carcinoma-
associated O-glycosylation. We have found that one of these enzymes, GalNAc-T3, is 
overexpressed in human pancreatic cancer tissues, and suppression of GalNAc-T3 significantly 
attenuates growth of pancreatic cancer cells in vitro and in vivo. In addition, suppression of 
GalNAc-T3 induces apoptosis of pancreatic cancer cells. Our results indicate that GalNAc-T3 is 
likely to be involved in pancreatic carcinogenesis. Modification of cellular glycosylation occurs in 
nearly all types of cancer as a result of alterations in the expression levels of glycosyltransferases. 
We report guanine nucleotide binding protein, alpha transducing activity polypeptide 1 (GNAT1) 
as a possible substrate protein of GalNAc-T3. GalNAc-T3 is associated with O-glycosylation of 
GNAT1, and affects the subcellular distribution of GNAT1. Knocking down endogenous GNAT1 
significantly suppresses the growth/survival of PDAC cells. Our results imply that GalNAc-T3 
contributes to the function of O-glycosylated proteins and thereby affects the growth and survival 
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of pancreatic cancer cells. Thus, substrate proteins of GalNAc-T3 should serve as important 
therapeutic targets for pancreatic cancers.
Keywords
polypeptide N-acetylgalactosaminyl-transferase; GalNAc-T3; pancreatic cancer; O-glycosylation; 
cell growth; apoptosis
Introduction
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of death by cancer in 
the western world. It shows the worst mortality among common malignancies with a 5-year 
survival rate of less than 5% (Jemal et al., 2009; Wray et al., 2005). Thus, the development 
of novel approaches to prevent and treat PDAC is important.
Pancreatic O-glycosylated proteins have important biological functions, including the 
protection, lubrication, and moisturization of the surfaces of epithelial tissues that line ductal 
structures within the pancreas. Both the glycosylation and expression of O-glycosylated 
proteins become deregulated during the development and progression of PDAC (Moniaux et 
al., 2004). The O-glycosylation of glycoproteins is critical for their function to protect and 
control the local environment of the cell surface, whereby aberrant glycosylation of O-
glycosylated proteins contributes to the transformation and metastatic capacity of cancer 
cells (Hollingsworth and Swanson, 2004). GalNAc-Ts are localized in the Golgi apparatus 
where mucin-type linkages (GalNacα1-O-Ser/Thr) are initiated. Once synthesized, 
GalNacα1-O-Ser/Thr can be additionally processed by different glycosyltransferases to form 
different core structures, such as Core1 (Galβ1-3GalNAcα-O-Thr/Ser) and Core2 
[GlcNAcβ1-6(Galβ1-3)GalNAcα-O-Thr/Ser]. Carbohydrates of glycoproteins, which are 
displayed on cell membranes, are structurally changed during carcinogenesis (Hakomori, 
1989). This carbohydrate heterogeneity has been applied to tumor markers for clinical 
diagnosis. For example, carbohydrate Antigen 19–9 (CA19-9) and carcinoembrionic antigen 
(CEA) are commonly used as markers of PDAC. Structural changes to the carbohydrates of 
glycoproteins may occur as a result of alterations in the expression levels of 
glycosyltransferases, which are implicated in the biosynthesis of glycoforms (Kondo A et 
al., 2006). Analysis of tissue-specific expression of these enzymes revealed that GalNAc-T3 
is overexpressed by some PDAC cell lines (Sutherlin et al., 1997). Thus, overexpression of 
GalNAc-T3 may contribute to the function of O-glycosylated proteins produced by PDAC 
cells and thereby affect the ability of these cells to transform and survive in different organ 
environments.
In this study, we show that GalNAc-T3 is overexpressed in human PDAC tissues, and that 
overexpression of GalNAc-T3 correlates with oncogenic activity. Suppression of GalNAc-
T3 expression in PDAC cells by RNA interference (RNAi) results in growth suppression of 
cancer cells in vitro and in vivo. We also report that GNAT1 may be a substrate protein of 
GalNAc-T3 and play a similarly important role in the viability of PDAC cells. It is likely 
that GalNAc-T3 acts on substrate proteins that are important for the growth and/or survival 
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of PDAC cells, and contributes to cell growth/survival in an epigenetic manner based on 
their substrate specificities.
Results
Overexpression of GalNAc-T3 in PDAC
We compared the expression levels of GalNAc-Ts in human PDAC cell lines with the 
normal pancreatic ductal cell line, HPNE, by semiquantitative reverse transcription-PCR 
(RT-PCR). We found that high levels of GalNAc-T3 expression were present in six of eight 
PDAC cell lines when compared to HPNE cells (Figure 1a). Overexpression of GalNAc-T3 
was confirmed by immunoblotting (Figure 1a).
Immunohistochemical analysis of GalNAc-T3 expression in human PDAC tissues using an 
anti-GalNAc-T3 antibody showed strong signals in the cytoplasm of PDAC cells in four 
PDAC tissue sections from five patients. The expression of GalNAc-T3 in two cases of 
PDAC is shown in Figure 1b. In normal pancreatic tissues, GalNAc-T3 is weakly expressed 
in the acinar and ductal epithelium (Figure 1c). Furthermore, tissue-microarray analysis of 
32 PDAC tissues shows that 21 of 32 PDACs express high levels of GalNAc-T3 (66%; 
Supplementary Table 1). Taking together all of the GalNAc-T3-positive PDAC specimens 
and the tissue microarray, immunohistochemical patterns show granular staining mostly 
restricted to the perinuclear areas in the cytoplasm in the center and in the surrounding areas 
of the tumors (Figure 1d, e).
Knockdown effects of GalNAc-T3 on the viability of PDAC cells
To assess whether GalNAc-T3 is essential for the growth of PDAC cells, we produced three 
independent RNAi constructs in the pSUPER system that targets GalNAc-T3. These 
constructs were transiently expressed in the moderately differentiated human PDAC cell 
lines S2-013 and BxPC3 in which GalNAc-T3 is highly expressed, and in the poorly 
differentiated human PDAC cell line PANC-1, which is GalNAc-T3 null. A knockdown 
effect by the siT3-1 and siT3-2 constructs was confirmed by RT-PCR and immunoblotting 
in S2-013 (Figure 2a). The effects of GalNAc-T3 on cell growth were determined from in 
vitro tissue culture assays. We found by colony-formation (Figure 2b) and MTT assays 
(Figure 2c) that S2-013 cells transfected with siT3-1 and siT3-2 were drastically reduced in 
number when compared with siT3-3, of which only a weak knockdown effect was apparent. 
Similar effects were obtained with the BxPC3 cell line; however, no significant differences 
were observed in PANC-1 cells in which GalNAc-T3 was not expressed (Figure 2d). These 
results suggest that GalNAc-T3 plays a role in PDAC cell viability.
Stable knockdown of GalNAc-T3 in PDAC cell lines by RNAi
To further examine the effects of GalNAc-T3 on cell growth/survival, motility, and 
invasion, we generated clones that stably suppressed GalNAc-T3 expression by vector-based 
transfection of the siT3-2 plasmid in S2-013 cells, which express high levels of GalNAc-T3. 
Western blot analysis validated that stable GalNAc-T3 RNAi clones (siT3-clone1 and siT3-
clone2) significantly suppressed GalNAc-T3 in S2-013 cells (Figure 3a). We also prepared 
control S2-013 cells transfected with a mock and a scrambled control vector (Neo-clone1 
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and Scr-clone1) to compare cell growth, motility, and invasion by in vitro culture assays and 
by an in vivo xenograft model. MTT assays showed that siT3-clone1 and siT3-clone2 grew 
much more slowly than control Neo-clone1 or Scr-clone1 (Figure 3b), in accordance with 
the results of MTT assays using transiently suppressed GalNAc-T3 (Figure 2c). These 
results indicate that lower levels of GalNAc-T3 expression suppress cell growth. 
Suppression of GalNAc-T3 fails to enhance or inhibit motility, as assessed by wound 
healing and transwell motility assays as well as by Matrigel invasion assays (data not 
shown).
We next examined the effect of suppressing GalNAc-T3 on tumor xenograft growth in nude 
mice. GalNAc-T3-silenced S2-013 clones displayed significantly decreased tumor growth 
kinetics compared with control xenografts (Figure 3c; 10 xenografts of 2 clones per group). 
This suggests that the loss of function of GalNAc-T3 suppresses the growth of xenografted 
PDAC tumors and that GalNAc-T3 might be involved in accelerating tumorigenesis in vivo.
Knockdown effects of GalNAc-T3 on apoptosis
We characterized the function of GalNAc-T3 in cell survival and determined the percentage 
of cells undergoing apoptosis between stable control and GalNAc-T3 S2-013 clones by flow 
cytometric analysis. ModFit cell cycle analysis software was used to analyze the percentage 
of cells undergoing apoptotic cell death. We found that the percentage of apoptotic cells 
increased when GalNAc-T3 was knocked down (Figure 4a, b). We calculated that 11.3 ± 
0.3% of siT3-clone1 and 7.1 ± 2.9% of siT3-clone2 of S2-013 cells were undergoing 
apoptosis, whereas in control mock and scrambled cells, a basal level of 0.8 ± 0.4% and 0.8 
± 0.8% apoptotic cells was detected, respectively (Figure 4c). Moreover, by FACS analysis, 
suppression of GalNAc-T3 increased the number of cells at sub-G1, which coincides with 
the increased apoptotic cell population (Figure 4d). Thus, suppression of GalNAc-T3 
drastically attenuates growth of PDAC cells and induces apoptosis, suggesting an essential 
role for GalNAc-T3 in maintaining the viability of PDAC cells.
GalNAc-T3 plays a role in inducing cell growth and survival
As shown in Figure 5a and in accordance with our flow cytometric data, we found a 
significantly higher number of apoptotic cells in GalNAc-T3 RNAi S2-013 cells as 
determined by in situ TUNEL staining. Additionally, the effect of GalNAc-T3 on cell 
proliferation was further studied by MIB-1 staining with control and GalNAc-T3 RNAi 
S2-013 cells (Figure 5b). MIB-1 recognizes the Ki-67 nuclear antigen, which is associated 
with cell proliferation and is found throughout the cell cycle (G1, S, G2, and M phases) but 
not in resting (G0) cells (Cattoretti et al., 1992). MIB-1 positive cells were significantly 
reduced in GalNAc-T3 depleted cells. To investigate the mechanism by which GalNAc-T3 
induces cell growth/survival, the activities of extracellular signal regulated kinases 1 and 2 
(ERK1/2), Akt, and prosurvival nuclear factor κB (NFκB) were assessed. The suppression 
of GalNAc-T3 did not change the phosphorylation levels of any of these molecules linking 
proliferation and apoptosis (data not shown).
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Identification of GNAT1 as a substrate protein of GalNAc-T3
To identify the target candidates of GalNAc-T3, we identified differently expressed proteins 
in the membrane fractions of stable control and GalNAc-T3 RNAi S2-013 cells by silver 
staining SDS-PAGE gels. O-glycosylated proteins generally attach to membrane and cell 
surfaces (Spiro 2002; Jensen 2006); thus, isolating subcellular fractions is useful for 
enriching membrane and membrane-associated proteins. Carbohydrate structural changes 
may occur as the result of alterations in the levels of glycosyltransferases, and glycosylation 
can alter the charge, conformation, and stability of proteins, and thereby induce 
heterogeneous protein profiles as a consequence of producing variable glycoforms (Kondo 
et al., 2006). Two 40-kDa bands were identified in GalNAc-T3 RNAi S2-013 cells, whereas 
only one band was observed in the control cells (Figure 6a). The 40-kDa bands were excised 
and analyzed by Q-TOF-MS after in-gel trypsin digestion, and identified as GNAT1. The 
peptide sequence coverage was 13% (Figure 6b). GNAT1 is a membrane-associated 3-
subunit guanine nucleotide-binding protein (G protein), which stimulates the coupling of 
rhodopsin and cGMP-phoshodiesterase during visual impulses (Ruiz-Avila et al., 1995). The 
function of GNAT1 in PDAC cells is currently unknown. Two bands of GNAT1 (40-kDa-1 
and −2) were confirmed in membrane fractions from GalNAc-T3 RNAi S2-013 cells by 
western blotting (Figure 7a). Only one band was observed in the control S2-013 cells (40-
kDa-2; Figure 7a). Additionally, both of the 40-kDa GNAT1 bands were more abundantly 
expressed in the cytoplasmic fractions of GalNAc-T3 RNAi S2-013 cells compared to 
control cells (Figure 7b). In immunocytochemical staining, GNAT1 was observed in the 
cytoplasm and membranes of GalNAc-T3 RNAi S2-013 cells, whereas GNAT1 was 
expressed at the cell membranes and only a little expression of GNAT1 was seen in the 
cytoplasm of control cells (Figure 7c). Thus, suppression of GalNAc-T3 produced a 
different form of GNAT1 (40-kDa-1) and changed its intracellular distribution. To test if 
GalNAc-T3 affects the stability of the GNAT1 protein, we analyzed GNAT1 mRNA and 
protein expression levels in total lysates of control S2-013 and GalNAc-T3 RNAi cells. We 
found no differences in mRNA expression of GNAT1 between control and GalNAc-T3 
RNAi S2-013 cells (Figure 7d); however, the steady-state level of 40-kDa-2, which is 
expressed in control cells, was decreased, and the altered 40-kDa-1 form was produced after 
GalNAc-T3 knockdown (Figure 7e). It is possible that knocking down endogenous GalNAc-
T3 decreased the stability of the 40-kDa-2 form, perhaps by carbohydrate structural changes 
or a loss of O-glycosylation, and in turn produced the 40-kDa-1 form. These results suggest 
that GalNAc-T3 post-translationally catalyzes GNAT1, and that GNAT1 may be a substrate 
protein of GalNAc-T3.
Identification of O-glycosylation in GNAT1
We next assessed the O-glycosylation status of GNAT1 in S2-013 cells. First, total lysates 
from S2-013 cells were treated with sialidase to determine the effects of removing sialic acid 
residues from O-glycans or N-glycans in GNAT1 (Figure 8a). Mobility shifts before and 
after sialidase treatment showed that GNAT1 from S2-013 cells was sialidase-sensitive. This 
result indicates that GNAT1 is a glycoprotein that has O-glycans or N-glycans. To test 
whether the carbohydrates of GNAT1 were O-glycosylated, total S2-013 cell lysates were 
treated with peptide N-glycosidase F (PNGase) to remove the N-linked glycans (Figure 8b). 
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We confirmed that the band of the single-span transmembrane N-glycoprotein E-cadherin 
was PNGase-sensitive, and found no obvious differences in band positions of GNAT1, thus 
indicating that GNAT1 is not glycosylated by N-linked carbohydrates. Additionally, S2-013 
cell lysates were incubated with O-sialoglycoprotein endopeptidase (OSGE; Mellors and Lo, 
1995), which cleaves the protein at O-linked glycans (Figure 8c). The GNAT1 band was 
significantly reduced after OSGE treatment. These results indicate that GNAT1 is an O-
glycosylated glycoprotein.
We next assessed the potential O-glycosylation of GNAT1 in GalNAc-T3 RNAi S2-013 
cells. The 40-kDa-1 form was not digested by OSGE treatment, whereas the 40-kDa-2 form 
was OSGE-sensitive (Figure 8d). A non-specific band was detected by western blotting 
using anti-GNAT1 antibody (Figure 8a, c, d). This band was at a much lower molecular 
weight than the apparent molecular weight of GNAT1, was seen in cell lysates with or 
without enzyme treatment, and was not shifted by the treatment. Thus, these results indicate 
that this band is not associated with GNAT1. Subsequently, the glycochain of GNAT1 was 
detected by a G-P sensor kit as the same sized molecule recognized by western blotting in 
control cells (Figure 8e). In concordance with the results shown in Figures 7e and 8d, the 
40-kDa-2 form was decreased and the 40-kDa-1 form was not detected in GalNAc-T3 RNAi 
S2-013 cells (Figure 8e). These results indicate that the 40-kDa-1 form was not O-
glycosylated by knocking down GalNAc-T3, and that GNAT1 is a specific substrate of 
GalNAc-T3.
Knockdown effects of GNAT1 on the viability of PDAC cells
MTT assays were used to examine the effect of reduced GNAT1 expression on cell growth 
of S2-013 cells, in which GNAT1 was highly expressed, and in GNAT1 null PANC-1 cells. 
As shown by western blot analysis, GNAT1 expression was markedly reduced in S2-013 
cells 72 h after transfection with the GNAT1-targeting siRNA-oligonucleotide, in contrast to 
cells transfected with the scrambled siRNA-oligonucleotide (Figure 9a). As a consequence 
of reduced GNAT1 expression by siRNA, a significant decrease in S2-013 cell growth was 
observed; however, no significant differences were observed in PANC-1 cells in which 
GNAT1 was not expressed (Figure 9b). Additionally, suppression of GNAT1 in S2-013 
cells decreased cell growth as assessed by MIB-1 staining (Figure 9c), and increased 
apoptosis in in situ TUNEL staining (Figure 9d). These studies demonstrate an important 
role of GNAT1 in PDAC cell viability.
Discussion
O-glycosylated proteins are associated with the differentiation and the malignant potential of 
cancers, such as altered cell adhesion, invasion, metastasis, recurrence, and prognosis 
(Brockhausen, 1999). In numerous pancreatic pathologic situations, O-glycosylated protein 
expression is deregulated, and aberrant expression of O-glycosylated proteins is often 
associated with a poor prognosis (Braga et al., 1992; Reis et al., 1999). O-glycosylation is 
important in many aspects of survival and protection of cells and organisms. Carcinomas 
commonly overexpress O-linked glycans in the form of cell-surface and secreted 
glycoproteins that present ligands for adhesion receptors, such as the selectins, which 
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promote the ability of tumor cells to interact with host platelets, leucocytes, and endothelial 
cells (Fuster and Esko, 2005). Thus, GalNAc-Ts that regulate the initiation of O-
glycosylation of glycoproteins are important for understanding aspects of tumor-associated 
aberrant O-glycosylation. We found GalNAc-T3 to be overexpressed in 66% of PDACs 
when compared with normal pancreas. O-glycosylation is carried out in part by the 
differential expression of GalNAc-Ts in normal tissues and tumors (White et al., 1995; 
Bennett et al., 1996), suggesting that the differential expression of O-linked carbohydrate 
antigens such as CA19-9 and CEA in PDAC may be explained by the differential expression 
and activity of specific GalNAc-Ts. Even though the extent of change in glycosylation due 
to malignancy or how clustered O-glycosylation occurs have not been studied in detail, 
overexpression of GalNAc-T3 in PDAC may be associated with aberrant production of 
tumor-associated O-glycosylation.
We demonstrated that suppression of GalNAc-T3 by RNAi significantly attenuates cell 
growth/survival of PDAC cells in vitro and in vivo. These results indicate that overexpressed 
GalNAc-T3 in PDAC cells is capable of O-glycosylation in a differential manner as 
compared to normal pancreatic epithelium, and that the formation of uncommon structures 
or novel sites of glycosylation due to aberrant glycosylation could contribute to malignant 
behavior. Because carbohydrates cannot be mutated directly, it is likely that GalNAc-T3 acts 
on substrate proteins that are important for the growth and/or survival of PDAC cells, and 
thereby contributes to cell growth/survival in an epigenetic manner based on the substrate 
specificities of these proteins. By Q-TOF analysis of control and GalNAc-T3 RNAi S2-013 
cells, we identified a membrane-associated G-protein, GNAT1, as a substrate candidate for 
GalNAc-T3. We showed that by knocking down endogenous GNAT1, the growth/survival 
of PDAC cells was significantly suppressed, implying that GalNAc-T3 may function to 
induce cell viability through abnormal glycosylation of its substrates.
The mechanism by which knockdown of GalNAc-T3 decreases cell viability in S2-013 cells 
is by inhibiting proliferation and inducing apoptosis. Cell proliferation and apoptosis are 
linked by cell-cycle regulators and apoptotic stimuli that affect both processes (Alenzi, 
2004). The phosphatidylinositide-3-OH kinase (PI3K)/Akt and the mitogen-activated protein 
kinase (MAPK)/ERK pathways have central roles in the regulation of cell proliferation and 
survival (Merighi et al., 2006). NFκB promotes cell survival through the expression of 
genes encoding anti-apoptotic proteins that directly block caspase activation (Andersen et 
al., 2005). In our study, GalNAc-T3 did not change the activity of ERK1/2, Akt, or NFκB, 
and the signal transduction pathway involved in GalNAc-T3-stimulated PDAC cell growth/
survival is still unknown.
GNAT1 is an essential G-protein in the rod phototransduction pathway, and converts light 
stimulation of photoreceptor opsins into the activation of cyclic GMP phosphodiesterase 
(Ruiz-Avila et al., 1995). The post-translational modifications of GNAT1 are currently 
unknown. We showed that GNAT1 is an O-glycosylated protein (Figure 8a-c, e), and that 
the increased molecular size of GNAT1 (the 40-kDa-1 form) produced by GalNAc-T3 
knockdown has no O-glycans (Figure 8d, e). This indicates that GalNAc-T3 is associated 
with cancer-associated O-glycosylation of GNAT1. We noted that GNAT1 in control 
S2-013 cells remains bound to membranes (Figure 7a, c), and knocking down GalNAc-T3 
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changed the subcellular distribution of GNAT1 from the plasma membrane to the cytoplasm 
(Figure 7b, c). It is possible that the 40-kDa-1 form of GNAT1 produced by GalNAc-T3 
knockdown is predominantly expressed in the cytoplasm due to loss of O-glycosyl 
structures. When rod GNAT1 is stimulated by light, its subunits dissociate, leave the 
membrane, and equilibrate throughout the rod cell (Rosenzweig et al., 2007). Cone 
transducin subunits do not dissociate during activation and remain sequestered within the 
membranes, indicating that the subunits of GNAT1 remain associated during activation in 
their native environments (Rosenzweig et al., 2007). Our results suggest a new and unique 
finding in PDAC cells, that the altered structure of O-glycans of GNAT1 could reflect its 
membrane affinity and intracellular distribution.
It has been known that malignant transformation is associated with abnormal glycosylation, 
resulting in expression of altered carbohydrate determinants (Kannagi et al., 2004). 
Knockdown of either GalNAc-T3 or GNAT1 significantly attenuated growth and survival of 
PDAC cells, and thus it is likely that the 40-kDa-2 form of GNAT1 is associated with cell 
viability; however, the 40-kDa-1 form produced by GalNAc-T3 knockdown does not 
function to increase cell growth/survival. The underexpression, truncation, or altered 
branching patterns of certain glycans correlate with cell growth (Fuster and Esko, 2005). 
Altered O-glycans expressing terminal galactose in pancreatic and colon cancers suppress 
apoptosis, possibly through binding to a member of the β-galactoside-binding proteins, 
galectin-3 (Takenaka et al., 2004). Other studies have demonstrated that upregulated 
biosynthesis of complex O-glycosidically-linked glycans and galectin-3 favor breast cancer 
progression and brain metastasis (Mayoral et al., 2008; Li et al., 2010). Thus, a change in O-
glycosylation of GNAT1 could contribute to a change towards a cancer phenotype and to 
malignant behavior. Future studies are essential for determining the structure and sites of O-
glycans in GNAT1 by analyzing the O-glycans released from GNAT1 by OSGE digestion 
by the use of mass spectrometry. Furthermore, the differences between the 40-kDa-1 and 40-
kDa-2 forms should be determined in order to evaluate whether structural changes occur as a 
result of alterations in the expression levels of GalNAc-T3. Thus, further studies are needed 
to identify the substrate O-glycosylated proteins of GalNAc-T3 that are essential for cell 
growth and/or survival of PDAC cells. Given the broad spectrum of O-glycoforms that are 
catalyzed by GalNAc-T3 on substrate proteins, these proteins should be promising targets 
for the development of novel drugs for PDAC patients.
Materials and Methods
Cell culture
Human PDAC cell lines PANC-1, BxPC3, SUIT-2, COLO357, HPAF, and MIA-PaCa2 
were purchased from the American Type Culture Collection (ATCC). Human PDAC cell 
line S2-013, which is a subline of SUIT-2, was obtained from Dr. T. Iwamura (Iwamura et 
al., 1987). HPNE immortalized normal pancreatic epithelial cells were a kind gift from Dr. 
Ouellette (Lee et al., 2005). Cells were grown in Dulbecco’s modified Eagle’s medium 
(DMEM; Gibco-BRL, Carlsbad, CA) supplemented with 10% heat-inactivated fetal calf 
serum at 37 °C saturated with 5% CO2 in a humidified atmosphere.
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Antibodies
Polyclonal antibodies against human GalNAc-T3 were generated by multiple immunizations 
of a New Zealand white rabbit using synthetic peptides as described previously (Nomoto et 
al., 1999). Rabbit anti-GNAT1 antibody (ab3504) was purchased from Abcam (Cambridge, 
MA). Chicken Alexa 488-conjugated anti-rabbit IgG secondary antibody was obtained from 
Molecular Probes (Carlsbad, CA).
Generation of stable knockdown cell lines of GalNAc-T3
We used a pSUPERgfp vector (OligoEngine, Seattle, WA) for expression of siRNA. The 
target sequences for the scrambled negative control and GalNAc-T3 were 5′-
TTCTCCGAACGTGTCACGT-3′ and 5′-GGTCTGATCACTGCTCGGT-3′, respectively. 
S2-013 cells were transfected with empty Neo-pSUPERgfp, a scrambled oligo-pSUPERgfp 
negative control, or a plasmid designed to express siRNA to GalNAc-T3, using FuGENE6 
(Roche, Penzberg, Germany). Cells were selected in medium containing 500 μg/mL of 
geneticin to generate stable pSUPERgfp cell lines. Single clones were isolated and analyzed 
for protein levels by western blotting.
Mice and xenografts
Female athymic nude mice (NCr-nu/nu) 7 weeks of age and specifically pathogen-free were 
purchased from the National Cancer Institute. Mice were treated in accordance with the 
Institutional Animal Care and Use Committee guidelines. A suspension of 8 × 105 cells of 
stable control (2 clones, total 10 mice) or GalNAc-T3 RNAi (2 clones, total 10 mice) 
derivative from S2-013 in 50 μL Hank’s balanced Salt Solution was injected s.c. into the 
dorsa of mice at the proximal midline. The tumors were measured every 5 to 7 days in two 
diameters with a dial caliper. Volumes were determined using the formula a2× b × 0.52 
(where a is the shortest and b is the longest diameter). All mice were sacrificed at the 
completion of the experiment, and tumors were fixed in 10% buffered formalin and paraffin 
embedded.
Flow cytometric analysis of apoptosis
Stable control and GalNAc-T3 RNAi cells of S2-013 were analyzed for apoptotic cell 
population by flow cytometry as previously described (Joshi et al., 2001). Briefly, 1 × 106 
cells were harvested by trypsinization and fixed in 70% ethanol. The cells were resuspended 
in 1 ml of Telford reagent containing EDTA (33.62 μg), RNase A (2.5 U), propidium iodide 
(50 μg), Triton X-100 (1.0 μl), and PBS (to a total volume of 1 ml). Cells were incubated at 
4 °C for 24 h and analyzed with a BD FACSCalibur flow cytometer (Becton Dickinson, 
Franklin Lakes, NJ) using Cell Quest Acquisition Software (Becton Dickinson) for data 
acquisition. Following data collection, cell cycle distribution and apoptosis was modeled 
using ModFit LT (Verity Software House, Topsham, ME; Gray et al., 1980). The correlation 
between the flow cytometric data that measures the apoptotic peak and DNA laddering has 
been described previously (Telford et al., 1991).
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In situ TUNEL assay
Manifestations of cell death were observed using fluorescent in situ terminal 
deoxynucleotidyl transferase-mediated uridine 5′-triphosphate-biotin nick end labeling 
(TUNEL staining). Cells were fixed with 4% formaldehyde, and the TUNEL reaction 
mixture was obtained by adding terminal deoxynucleotidyl transferase to a nucleotide 
mixture, as instructed by the manufacturer’s manual (Roche). Cells were then incubated 
with 50 μL TUNEL reaction mixture at 37 °C in the dark for 60 min. After rinsing with 
PBS, the nuclei of the specimens were counterstained with DAPI and visualized with a Zeiss 
LSM510 META microscope (Carl Zeiss, Gottingen, Germany).
Cytosol and membrane fractionation
Cells were homogenized in hypotonic buffer [20 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1 
mM EDTA, 1 mM PMSF, 1 mM Na3VO4] using a Dounce homogenizer, centrifuged at 700 
× g for 5 min, and the postnuclear supernatant was then centrifuged at 100,000 × g for 1 h. 
The resulting supernatant was collected and used as the cytosolic fraction. The pellet was 
resuspended in hypotonic buffer containing 1% Triton X-100 and incubated on ice for 1 h. 
The supernatant component (particulate fraction) was centrifuged at 14, 000 × g for 20 min. 
Protein concentrations were determined by the Bio-Rad protein assay using BSA as a 
standard.
Mass spectrometric analysis
The membrane fractions from the stable scrambled negative control and GalNAc-T3 RNAi 
S2-013 cells were separated by 4–20% gradient SDS-PAGE and silver-stained. Bands that 
distinguished the proteins by knockdown of GalNAc-T3 from those in control cells were 
excised, digested in-gel with trypsin, and analyzed using a Q-TOF Ultima tandem mass 
spectrometer (Waters, Milford, MA) with electrospray ionization. Database searches of the 
acquired MS/MS spectra were performed using MASCOT v1.9.0 (Matrix Science, London, 
UK).
Enzyme treatment
Total cell lysates were treated with either 0.2 U/mL of sialidase (Roche) for 4 h at 37 °C, 
100 units of peptide N-glycosidase F (New England BioLabs, Ipswich, MA) for 1 h at 37 
°C, or 120 μg/mL O-sialoglycoprotein endopeptidase (Cedarlane, Ontario, Canada) for 4 h at 
37 °C, and then analyzed by western blotting with anti-GNAT1 antibody.
Detection of sugar chains of GNAT1
S2-013 cells were lysed in lysis buffer [20 mM HEPES (pH 7.4), 100 mM KCl, 5 mM 
MgCl2, 0.5% Triton X-100, and protease inhibitor cocktail tablets (Roche)], and incubated 
with 2 μg of anti-GNAT1 antibody and protein G Sepharose. The detection of glycochains 
of GNAT1 was carried out with the use of a commercially available kit, G. P. Sensor 
(Honen, Tokyo, Japan). After immunoprecipitated GNAT1 was analyzed by western 
blotting, GNAT1 immobilized on the PVDF membrane was subjected to periodate 
oxidation. The aldehyde group formed by the periodate oxidations was coupled with biotin 
hydrazide. Biotin hydrazide-sugar chains were then coupled with streptavidin-horseradish 
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peroxidase (HRP) conjugate. The HRP-labeled glycochains of GNAT1 were detected by 
enhanced chemiluminescence.
siRNA treatment
RNAi targeting GNAT1 and scrambled negative control siRNA oligonucleotides were 
purchased from Santa Cruz Biotechnology (43783 and 37007; Santa Cruz, CA). To examine 
the effect of the siRNAs on GNAT1 expression, S2-013 cells that expressed GNAT1 and 
PANC-1 cells that did not express GNAT1 were plated in six-well plates. After 20 h, the 
cells were transfected with 80 pmols of siRNA in siRNA transfection reagent (Santa Cruz) 
following the manufacturer’s instructions. After 72 h incubation, the cells were used for 
western blot analysis and MTT assays.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Overexpression of GalNAc-T3 in PDAC
(a) Expression of endogenous GalNAc-T3 in PDAC cells compared with the HPNE cell 
line, as determined by RT-PCR (upper panels) and western blotting using anti-GalNAc-T3 
antibody (lower panels).
(b) Immunohistochemical staining of PDAC tissues using anti-GalNAc-T3 antibody. 
Original magnification: 200×.
(c) Immunohistochemical staining of normal pancreas tissues using anti-GalNAc-T3 
antibody. Original magnification: 200×. (d and e) Representative expression pattern of 
GalNAc-T3 in two PDAC cases. In these cases, granular-staining was seen at the center and 
surrounding the tumors. Original magnification: 200×.
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Figure 2. Growth-inhibitory effect of GalNAc-T3 siRNAs in PDAC cells
(a) Three GalNAc-T3 siRNA expression vectors (siT3-1, siT3-2, and siT3-3) and a Neo-
pSUPERgfp vector as a negative control were transiently transfected into S2-013 cells. The 
knockdown effect of GalNAc-T3 was validated by RT-PCR (upper panels) and western 
blotting using anti-GalNAc-T3 (lower panels).
(b) Colony formation assays of S2-013 cells were carried out 14 days after neomycin 
selection. Data are representative of three independent experiments.
(c) MTT assays of S2-013 cells were performed to evaluate cell viability at 14 days with 
neomycin selection. Data are representative of three independent experiments and are shown 
as means ± SEM. *p < 0.001 and **p < 0.005 compared with control cells.
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(d) MTT assays of BxPC3 and PANC-1 cells were performed to evaluate cell viability at 14 
days with neomycin selection. Data are representative of three independent experiments and 
are shown as means ± SEM. *p < 0.001 and **p < 0.005 compared with control cells.
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Figure 3. Stable knockdown of GalNAc-T3 suppresses cell growth of PDAC
(a) Western blot with anti-GalNAc-T3 antibody showing two S2-013 (siT3-clone1 and 2) 
clones transfected with siRNA for GalNAc-T3 and compared to mock (Neo-1) and 
scrambled (Scr-1) control clones.
(b) MTT assays in stable control and GalNAc-T3 RNAi S2-013 cells. Data are 
representative of three independent experiments and are shown as means ± SEM. *p < 0.001 
compared with control cells.
(c) Tumor xenografts in stable control and GalNAc-T3 RNAi S2-013 cells. Two control and 
GalNAc-T3 RNAi clones were incubated in the dorsa at the proximal midline of 7-week-old 
nude mice. n = 5; error bars indicate SEM; *p < 0.005 compared with control cells.
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Figure 4. Flow cytometric analysis of cell cycle distribution and apoptosis in stable control and 
GalNAc-T3 RNAi S2-013 cells
(a and b) Cells were grown to approximately 70% confluence and removed from the culture 
surfaces by trypsinization, and DNA content and apoptosis were determined. Raw data were 
modeled using ModFit cell cycle analysis software. The profiles are representative 
histograms of triplicate assays. a, control; b, GalNAc-T3 RNAi cells.
(c) The percentage of apoptotic cells is shown between control and GalNAc-T3 RNAi 
S2-013 cells. Experiments were repeated three times; *p < 0.001, **p < 0.005 compared 
with control cells.
(d) The percentage of cells in the sub-G1 population was determined from at least 10,000 
ungated cells between the control and GalNAc-T3 RNAi S2-013 cells. Experiments were 
repeated three times; *p < 0.05 compared with control cells.
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Figure 5. The effects of GalNAc-T3 on cell growth and survival
(a) Control and GalNAc-T3 RNAi S2-013 cells were subjected to an in situ apoptosis 
detection assay. The red signal indicates apoptosis. Blue, DAPI staining. The number of 
apoptotic cells was counted. Cells in four defined areas per group per experiment were 
quantified. Data are representative of three independent experiments. Columns, mean; bars, 
SD. *p<0.001 compared with control cells. Bar: 10 μm.
(b) Immunocytochemical staining in control and GalNAc-T3 RNAi S2-013 cells, as 
determined with anti-MIB-1 (green). Blue, DAPI staining. The percentage of MIB-1-stained 
cells is shown. Cells in four defined areas per group per experiment were quantified. Data 
are representative of three independent experiments. Columns, mean; bars, SD. *p<0.001 
compared with control cells. Bar: 10 μm.
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Figure 6. Identification of GalNAc-T3-associated proteins
(a) Membrane fractionated proteins from control and GalNAc-T3 RNAi S2-013 cells were 
examined by silver stain analysis.
(b) Percent coverage for GNAT1 is represented by the identified peptides in the total protein 
sequence (accession number NM_032166).
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Figure 7. GNAT1 is a potential substrate for GalNAc-T3
(a) Membrane fractionation of control and GalNAc-T3 RNAi S2-013 cells followed by 
western blotting using anti-GNAT1 antibody.
(b) Cytosolic fractionation of control and GalNAc-T3 RNAi S2-013 cells followed by 
western blotting using anti-GNAT1 antibody.
(c) Immunocytochemical staining in control and GalNAc-T3 RNAi S2-013 cells, as 
determined by anti-GNAT1 antibody (green) and DAPI staining (blue). Bars: 10 μm.
(d) RT-PCR analysis of steady-state levels of GNAT1 mRNAin control and GalNAc-T3 
RNAi S2-013 cells.
(e) Western blot of steady-state levels of GNAT1 protein in control and GalNAc-T3 RNAi 
S2-013 cells.
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Figure 8. GNAT1 is an O-glycosylated protein
(a) Total cell lysates from S2-013 cells were treated with sialidase, followed by western 
blotting with anti-GNAT1 antibody.
(b) Total cell lysates from S2-013 cells were treated with PNGase, followed by western 
blotting with anti-GNAT1 antibodyand anti-E-cadherin antibody as a positive control of 
PNGase treatment.
(c) Total cell lysates from S2-013 cells were treated with OSGE, followed by western 
blotting with anti-GNAT1 antibody.
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(d) Total cell lysates from GalNAc-T3 RNAi S2-013 cells (siT3-clone 1) were treated with 
OSGE, followed by western blotting with anti-GNAT1 antibody.
(e) Western blotting of immunoprecipitated GNAT1 from control and GalNAc-T3 RNAi 
S2-013 cells with anti-GNAT1 antibody and detection of glycochains of GNAT1.
Taniuchi et al. Page 22
Oncogene. Author manuscript; available in PMC 2012 June 12.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 9. GNAT1 induces cell growth and survival of PDAC cells
(a) siRNA oligonucleotides targeting GNAT1 (siGNAT1) and negative scrambled control 
(Scr) were transiently transfected into S2-013 and PANC-1 cells. Western blotting validated 
the knockdown effect of GNAT1 in S2-013 cells.
(b) MTT assays of S2-013 and PANC-1 cells were performed to evaluate cell viability. Data 
are representative of three independent experiments and are shown as means ± SEM. *p < 
0.005 compared with scrambled control cells.
(c) siRNA oligonucleotides targeting GNAT1 and negative scrambled control were 
transiently transfected into S2-013 cells. The percentage of MIB-1-stained cells is shown. 
Cells in four defined areas per group per experiment were quantified. Data are representative 
of three independent experiments. Columns, mean; bars, SD. *p<0.005 compared with 
control cells.
(d) Control and GNAT1 RNAi S2-013 cells were subjected to an in situ apoptosis detection 
assay. Cells in four defined areas per group per experiment were quantified. Data are 
representative of three independent experiments. Columns, mean; bars, SD. *p<0.005 
compared with control cells.
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Overexpression of GalNAc-transferase GalNAc-T3 Promotes Pancreatic Cancer Cell Growth 
 
 
Supplementary Materials and Methods 
 
Semiquantitative RT-PCR 
Total RNA extracted from eight pancreatic cancer (PDAC) cell lines (PANC-1, BxPC3, S2-013, 
SUIT-2, COLO357, HPAF, MIA-PaCa2, and Capan2), and HPNE immortalized normal pancreatic 
epithelial cells were subjected to reverse transcription with StrataScript reverse transcriptase 
(Agilent, La Jolla, CA) and oligo d(T)12-18 primer. We prepared appropriate dilutions of each single-
stranded cDNA for subsequent PCR amplification by monitoring GAPDH as a quantitative control. 
The primer sequences were 5’-TGAGAACTACACGGCTGTCG-3’ and 5’-
ATGGTTTGCCTCCTTGATTG-3’ for GalNAc-T3, and 5’-CGAGATCCCTCCAAAATCAA-3’ and 5’-
TTCAGCTCAGGGATGACCTT-3’ for GAPDH. All reactions involved initial denaturation at 94 °C 
for 2 min followed by 21 cycles for GAPDH or 28 cycles for GalNAc-T3 at 94 °C for 30 s, 58 °C for 
30 s, and 72 °C for 1 min. 
 
Immunohistochemical staining 
Tissue sections from PDACs were obtained from the rapid autopsy program approved by the 
Institutional Review Board of the University of Nebraska Medical Center. Informed consent was 
obtained from all patients. Tissue sections from normal pancreas were purchased from Biochain 
(Hayward, CA). Tissue-microarray sections of PDACs (A207I, AccuMax Array) were purchased 
from ISU ABXIS (Seoul, Korea), where 32 PDAC tissues were spotted in duplicate. The sections 
were incubated with anti-GalNAc-T3 antibody followed by incubation with peroxidase-labeled anti-
rabbit immunoglobulin (Envision kit; Dako Cytomation, Glostrup, Denmark). Finally, the reactants 
were developed with 3, 3’-diaminobenzidine (Dako) and the cells were counter-stained with 
hematoxylin. 
 
Construction of small interfering RNA expressing vector and cell viability assay 
The pSUPER-gfp vector (OligoEngine, Seattle, WA) was used for expression of small interfering 
RNA (siRNA) against GalNAcT-3. The siRNA oligonucleotide sequences for GalNAc-T3 are as 
follows: siT3-1, 5’-GCCTGTCCTTGACCGTCCA-3’; siT3-2, 5’-GGTCTGATCACTGCTCGGT-3’; 
and siT3-3, 5’-GCGTTGGTCAGCCTCTATG-3’. S2-013 and BxPC3 cells were plated onto six-well 
plates (4  104 cells/well) and transiently transfected with empty Neo-pSUPER-gfp as a negative 
control or pSUPER-gfp including the target sequence for GalNAc-T3, using FuGENE6 (Roche, 
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Penzberg, Germany), according to the manufacturer’s instructions. Cells were selected in medium 
containing 500 µg/ml of geneticin for 14 days and harvested after 48 h for RT-PCR analysis of the 
knockdown effect on GalNAcT-3. Primers for these RT-PCR experiments were the same as those 
described above. After 14 days of incubation in medium containing 500 µg/ml of geneticin, Giemsa 
staining was performed to count the number of colonies, and viability of cells was evaluated by 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Briefly, cell counting kit-8 
solution (Dojindo, Kumamoto, Japan) was added to each well at a concentration of 1/10 volume, 
and the plates were incubated at 37 °C for an additional 3 h. Absorbance was then measured at 
490 nm, and at 630 nm as a reference, with a Microplate Reader 550 (Bio-Rad, Hercules, CA). 
 
 
In vitro growth rate by MTT assay  
Stable GalNAc-T3 RNAi and control S2-013 cells were each seeded at a concentration of 5  104 
cells per well using 12-well plates. Cell viability was examined using the cell counting kit-8 solution 
as described above. The MTT assay was done every 24 h for 5 days, according to the 
manufacturer's instructions. 
 
Confocal immunofluorescence analysis  
Cells were fixed with 4% paraformaldehyde, then permeablilized with 0.1% Triton X-100, covered 
with blocking solution (3% BSA/PBS), and incubated with the primary antibody for 1 h. Alexa 488-
conjugated anti-rabbit IgG secondary antibody was used. Each specimen was visualized with a 
Zeiss LSM510 META microscope (Carl Zeiss, Gottingen, Germany). 
 
Statistical analysis 
The significance of differences between groups was determined using the Student’s t-test, Mann-
Whitney U test, or Fisher’s exact test, as appropriate. P < 0.05 was considered statistically 
significant. 
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Table S1 GalNAc-T3 staining in a pancreatic cancer tissue microarray 
Differentiation of 
pancreatic tumors (n) 
Strong GalNAc-T3 
expression 
Weak or absent 
GalNAc-T3 
expression  
Well (4) 3 1 
Moderate (13) 8 5 
Poor (9) 6 3 
ETC (6) 4 2 
ETC; Tumor cell differentiation is unknown according to the information from the ISU ABXIS. 
 
